TY - JOUR
T1 - Economic Evaluation of COVID-19 Screening Tests and Surveillance Strategies in Low-Income, Middle-Income, and High-Income Countries
T2 - A Systematic Review
AU - Purba, Abdul Khairul Rizki
AU - Rosyid, Alfian Nur
AU - Handayani, Samsriyaningsih
AU - Rachman, Brian Eka
AU - Romdhoni, Achmad Chusnu
AU - Al Farabi, Makhyan Jibril
AU - Wahyuhadi, Joni
AU - Prananingtias, Rosita
AU - Rahayu, Ainun Nitsa
AU - Alkaff, Firas Farisi
AU - Azmi, Yufi Aulia
AU - Sabarinah, Prasetyo
AU - Nadjib, Mardiati
AU - Gutjahr, Lina Patricia
AU - Humaidy, Raudia Faridah
N1 - Publisher Copyright:
© 2024 International Scientific Information, Inc.. All rights reserved.
PY - 2024
Y1 - 2024
N2 - Background: Economic evaluation of the testing strategies to control transmission and monitor the severity of COVID-19 after the pandemic is essential. This study aimed to review the economic evaluation of COVID-19 tests and to construct a model with outcomes in terms of cost and test acceptability for surveillance in the post-pandemic period in low-income, middle-income, and high-income countries. Material/Methods: We performed the systematic review following PRISMA guidelines through MEDLINE and EMBASE databases. We included the relevant studies that reported the economic evaluation of COVID-19 tests for surveillance. Also, we input current probability, sensitivity, and specificity for COVID-19 surveillance in the post-pandemic period.Results: A total of 104 articles met the eligibility criteria, and 8 articles were reviewed and assessed for quality. The specificity and sensitivity of COVID-19 screening tests were reported as 80% to 90% and 40% to 90%, respectively. The target population presented a mortality rate between 0.2% and 19.2% in the post-pandemic period. The implementation model of COVID-19 screening tests for surveillance with a cost mean for molecular and antigen tests was US$ 46.64 (min-max US $0.25-$105.39) and US $6.15 (min-max US $2-$10), respectively. Conclusions: For the allocation budget for the COVID-19 surveillance test, it is essential to consider the incidence and mortality of the post-pandemic period in low-income, middle-income, and high-income countries. A robust method to evaluate outcomes is needed to prevent increasing COVID-19 incidents earlier.
AB - Background: Economic evaluation of the testing strategies to control transmission and monitor the severity of COVID-19 after the pandemic is essential. This study aimed to review the economic evaluation of COVID-19 tests and to construct a model with outcomes in terms of cost and test acceptability for surveillance in the post-pandemic period in low-income, middle-income, and high-income countries. Material/Methods: We performed the systematic review following PRISMA guidelines through MEDLINE and EMBASE databases. We included the relevant studies that reported the economic evaluation of COVID-19 tests for surveillance. Also, we input current probability, sensitivity, and specificity for COVID-19 surveillance in the post-pandemic period.Results: A total of 104 articles met the eligibility criteria, and 8 articles were reviewed and assessed for quality. The specificity and sensitivity of COVID-19 screening tests were reported as 80% to 90% and 40% to 90%, respectively. The target population presented a mortality rate between 0.2% and 19.2% in the post-pandemic period. The implementation model of COVID-19 screening tests for surveillance with a cost mean for molecular and antigen tests was US$ 46.64 (min-max US $0.25-$105.39) and US $6.15 (min-max US $2-$10), respectively. Conclusions: For the allocation budget for the COVID-19 surveillance test, it is essential to consider the incidence and mortality of the post-pandemic period in low-income, middle-income, and high-income countries. A robust method to evaluate outcomes is needed to prevent increasing COVID-19 incidents earlier.
KW - Cost of Illness
KW - Epidemiology
KW - Mass Screening
KW - Mortality
KW - SARS-CoV-2
UR - http://www.scopus.com/inward/record.url?scp=85190966532&partnerID=8YFLogxK
U2 - 10.12659/MSM.943863
DO - 10.12659/MSM.943863
M3 - Review article
C2 - 38643358
AN - SCOPUS:85190966532
SN - 1234-1010
VL - 30
JO - Medical Science Monitor
JF - Medical Science Monitor
M1 - e943863
ER -